KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives

On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with ...

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...
Med Device OnlineOpinion

The Synthetic Control Mirage: Why Your Medtech RWD Strategy Will Fail In Latin America

Regulators are actively encouraging medtech companies to use real-world data and synthetic control arms. Heres why this is ...
News-Medical.Net on MSN

New publication describes the chemical journey of non-hormonal male birth control pill

A newly published manuscript authored by Dr. Gunda Georg, YourChoice Therapeutics and Columbia University Medical Center ...

Autologous T cell therapy targeting multiple antigens shows promise in treating pancreatic cancer

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...
BMJ Open

Virtual reality for visions (VRV): a proof-of-concept study examining the development of a new treatment for distressing visual hallucinations in people with psychosis

Introduction Visual Hallucinations (VHs) (seeing things that others do not, or visions) are a common feature of psychosis, causing significant distress and disability. Services rarely ask about these ...
Le Lézard

Health Canada approves RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes

Novo Nordisk announced today that Health Canada has approved RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction ...